Asia Pacific Bioreactors Market size was valued at USD 141.9 million in 2018 and is expected to witness 18.7% CAGR from 2019 to 2025.
Get more details on this report - Request Free Sample PDF
Asia Pacific bioreactors market is expected to witness considerable growth across the forecast timeframe. Growing demand for therapeutically active vaccines along with increasing prevalence of lifestyle diseases such as diabetes and cancer will augment business growth. Moreover, increasing biopharmaceutical investments coupled with growing contract manufacturing organizations will further boost demand for bioreactors, thus delivering a positive growth trajectory.
Rising prevalence of chronic diseases is a major growth propelling factor. Additionally, increasing product innovation and favourable government initiatives for the development of healthcare infrastructure will further drive business growth. Also, growing demand for personalised medicines coupled with increasing popularity of single-use bioreactors in various biopharmaceutical companies will positively aid in growth of bioreactors market across the projected timeframe.
However, the anticipated growth in the bioreactors market is likely to impede due to limitation in the capacity of single-use bioreactor. Moreover, use of disposable plastic bioreactors for biopharmaceutical manufacturing will be a market impeding factor owing to concerns related to extractables and leachable.
Asia Pacific Bioreactors Market, By Cell
Mammalian cell segment held maximum revenue shares accounting of USD 110.1 million in 2018. Mammalian cells are widely used in the biopharmaceutical industry to produce biological products. Mammalian cell expression system is a dominant technique for production of complex biotherapeutic proteins. Mammalian cells have the capacity of adding human-like post-translational modification to complex protein therapeutics, driving the bioreactors market size. Hence, growing demand for mammalian cells due to higher productivity and efficiency compared to prokaryotic cells will propel segmental growth.
Bacterial cell segment will witness lucrative growth of 18.6% during the forecast period. High growth rate is attributed to various benefits associated with bacterial cells. It provides bioreactors with the high mass transfer competence, permit rapid metabolism, and supports high-cell density microbial cell cultivation and growth in the quantity of product, thus augmenting segmental growth.
Asia Pacific Bioreactors Market, By Molecule
Recombinant proteins segment generated over USD 18.1 million in 2018. High growth is attributed to growing use of recombinant protein drugs for the treatment of several diseases, including rheumatic conditions and different types of cancer. The recombinant protein market has grown at a significant rate, demonstrating an economically robust future for the bioreactors industry. Hence, the above-mentioned factors will drive the Asia Pacific bioreactors market growth.
Stem cells segment will grow at about 18.7% from 2019 to 2025. Stem cell is an emerging field and has the potential for treatment, diagnosis, and drug discovery for various disorders. Stem cell treatment is used for curing cancer and neurological disorders. Increasing investments by companies for the development of cell-based treatments, intensive R&D efforts, rise in government funding, and an overall surge in demand for cell-based products from top biotechnology companies will drive the market growth.
Asia Pacific Bioreactors Market, By Technology
Wave-induced motion SUB segment accounted for revenue size of USD 75.0 million in 2018 and is expected to witness substantial growth across the forecast timeframe. Wave-induced motion technology is most widely used in modern biotechnological processes. These bioreactors offer moderate to high cell density and adequate productivity in laboratories. The technology enables simple, safe and flexible production, thus augmenting segmental growth.
Single-use bubble column technology segment is expected to witness favourable growth of 19.3% over the projected timeframe, owing to its huge demand in the biopharmaceutical industry. Bubble column bioreactors are expected to gain considerable attention in the upcoming years due to additional advantages over other reactors. Online catalyst addition, and plug-free operation are the factors that create high demand for the bubble columns, thus propelling market growth.
Asia Pacific Bioreactors Market, By End-use
Contract Manufacturing Organizations (CMOs) held about 18.1% of industry share in 2018. Outsourcing to Contract Manufacturing Organizations (CMOs) is one of the most prominent trend in the medical industry, particularly in the biopharmaceuticals market. Contract manufacturing organizations are used large number of processes in the healthcare industry and several players from emerging countries are entering the market, thus boosting segmental growth.
R&D organizations held the largest revenue of 68.9 million in 2018 and is projected to witness strong growth over the forecast years. Bioreactors are utilizing the excellent function of biocatalysts as organic catalysts; this continues to be one of the major drivers in the growing area of biotechnology. Hence, increasing promotion rate of bioreactor research programs by using biocatalysts to establish energy-saving and pollution-free process in the chemical and biopharmaceutical industry will augment R&D organizations segmental growth.
Asia Pacific Bioreactors Market, By Country
Japan bioreactors market recorded revenue size of USD 40.7 million in 2018. High growth is attributed to factors such as growing financial support from the government for the development of innovative drugs along with increasing number of biopharmaceutical companies in the region. Furthermore, technological developments associated with various single use bioreactors will also augment China bioreactors market growth.
India bioreactors market is estimated to witness substantial growth of 19.8% across the forecast period, owing to increasing technological adoption in the country. Additionally, the government is emphasizing on the development smart manufacturing infrastructure that will enable manufacturers to make real time use of bioreactors. Moreover, increasing healthcare spending will further boost market growth.
Some of the major industry players involved in Asia Pacific bioreactors market include Applikon Biotechnology, Inc., Cellexus Limited, CESCO Bioengineering Co. Ltd., Eppendorf AG, GE Healthcare, GEA Group Aktiengesellschaft, Merck Group, PBS Biotech, Inc, Pierre Guerin SAS, Sartorius Stedim Biotech Group, Shanghai Bailun Biotechnology co., Ltd., Solaris Biotech Solutions and Thermo Fisher Scientific Inc. Companies mainly focus on agreements, geographical expansion, new product launch, acquisition strategy and collaborations to stay ahead in the competition.
Asia Pacific Bioreactors Industry Background
Bioreactors are manufacturing devices that sustain biologically active environment. Production of enzymes, vaccines and other substances are done in bioreactors, through chemical processes that involves the use of biologically active derivatives from microbial organisms. During 1980’s, bioreactors were used initially for wastewater treatment in japan, owing to government initiatives for better ways of water purification. Growing demand for innovative biotech solutions such as single-use technology, pre-built modular facilities, and the ability to revamp and upgrade existing facilities in Asia Pacific will drive the industry growth over the forecast period. Similarly, major players such as, Shanghai Bailun Biotechnology co., Ltd., GEA Group Aktiengesellschaft, Sartorius Stedim Biotech Group, Merck Group and GE healthcare are emphasizing on increasing investment in R&D for the development of new technologies that focus on improving microbial culture, mixing and temperature control.